CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it will ...

Furthermore, CRISPR is a powerful research tool in regenerative medicine. It enables genetic screening to identify genes involved in differentiation and disease progression, and helps create ...

The company's path to creating life-changing returns hinges on its ability to deliver consistent clinical and regulatory wins ...

CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: EDIT), a pioneering gene editing company focused on developing ...

For years, researchers have been trying to figure out how to treat inherited blood disorders like sickle cell disease without ...

The results suggest that lung xenotransplantation could one day become an option, but they also point to how much more work ...

Editas Medicine announces advancements in in vivo CRISPR gene editing, optimizing costs, and reducing workforce while focusing on hematologic diseases.

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where Prime Medicine, Inc. (NASDAQ:PRME) stands against the other CRISPR stocks.

Furthermore, SNIPR technology is utilized to create CRISPR-medicine designed to convert and produce therapeutics selectively within targeted regions of the gastrointestinal tract.

The ability to correct disease-causing genetic mistakes using genome editors holds great promise in medicine, but it is not ...

Editas Medicine is developing a CRISPR gene editing system to address serious and rare conditions, such as sickle cell disease, beta thalassemia, and inherited eye disorders.